×
Upstream Bio Price to Free Cash Flow Ratio 1971-1970 | UPB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Upstream Bio price to free cash flow ratio from 1971 to 1970. Price to free cash flow ratio can be defined as
View More
Upstream Bio Price to Free Cash Flow Ratio 1971-1970 | UPB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Upstream Bio price to free cash flow ratio from 1971 to 1970. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.2B
Vertex Pharmaceuticals (VRTX)
$123.4B
Gilead Sciences (GILD)
$107.4B
Regeneron Pharmaceuticals (REGN)
$106.8B
Bristol Myers Squibb (BMY)
$105.7B
CSL (CSLLY)
$97.7B
GSK (GSK)
$79.1B
Alnylam Pharmaceuticals (ALNY)
$37.5B
Argenex SE (ARGX)
$33.5B
Biogen (BIIB)
$26.9B
BioNTech SE (BNTX)
$26.5B
Illumina (ILMN)
$23.1B
BeiGene (BGNE)
$21.4B
Moderna (MRNA)
$20.7B
Genmab (GMAB)
$15.1B
BioMarin Pharmaceutical (BMRN)
$13.3B
Vaxcyte (PCVX)
$12.9B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.4B
Sarepta Therapeutics (SRPT)
$12.1B
Bio-Techne Corp (TECH)
$11.2B
QIAGEN (QGEN)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8.4B
Exelixis (EXEL)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Revolution Medicines (RVMD)
$8B
Legend Biotech (LEGN)
$7.9B